13F-HR: Regeneron Discloses Q4 2025 Equity Holdings

Regeneron Pharmaceuticals, Inc. filed its Q4 2025 13F-HR report, revealing holdings primarily in Intellia Therapeutics and Adicet Bio totaling over $33.7 million.

Summary

• Regeneron Pharmaceuticals, Inc. filed a Form 13F Holdings Report for the calendar quarter ended December 31, 2025.
• The total market value of reported holdings was $33,799,428.
• The report disclosed two equity positions.
• Holdings include 3,702,995 shares of Intellia Therapeutics, Inc. Common Stock, valued at $33,289,925.
• Also held were 60,511 shares of Adicet Bio, Inc. Common Stock, valued at $509,503.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, providing transparency into Regeneron's equity investment portfolio without indicating significant positive or negative operational performance.

Positives

• Transparency in disclosing equity investments, providing insight into investment strategy.
• Strategic investments in biotechnology companies, aligning with Regeneron's core industry focus.

Negatives

• No specific negatives are apparent from this standard 13F filing, which primarily reports existing holdings.

Future Outlook

NA

Management Comments

• Leonard Brooks, Senior Vice President, Treasurer, signed the report, representing that the person signing is authorized to submit it and that all information is true, correct, and complete.

Industry Context

StockSavvy.ai notes that Regeneron's investment in other biotechnology companies, particularly those focused on gene editing (Intellia) and cell therapy (Adicet Bio), aligns with broader industry trends towards innovation in these high-growth therapeutic areas. This suggests a strategic interest in emerging biotech fields.

Comparison to Industry Standards

• Regeneron's investment in Intellia Therapeutics, a leader in CRISPR-based gene editing, positions it alongside other major pharmaceutical companies like Novartis and Bayer, which have also made significant investments or partnerships in gene therapy and editing technologies.
• The holding in Adicet Bio, focused on gamma delta T-cell therapies, reflects a broader industry trend where large biopharma companies are exploring novel cell therapy platforms beyond traditional CAR-T, similar to investments seen from companies like Johnson & Johnson or Gilead in next-generation cell therapies.

Stakeholder Impact

• Shareholders: Provides transparency into Regeneron's investment strategy and portfolio composition.
• Investment Community: Offers insights into Regeneron's views on specific biotechnology companies and their potential strategic interests.

Key Dates

Recommendation

This 13F filing provides a snapshot of Regeneron's equity investments as of December 31, 2025, primarily in other biotechnology firms. While it offers transparency into their investment strategy, it does not contain new financial performance data or strategic announcements for Regeneron itself that would warrant a change in investment recommendation. The disclosed holdings are consistent with a large pharmaceutical company's potential strategic interests in the biotech sector.

Keywords

Regeneron Pharmaceuticals, 13F, Institutional Holdings, Equity Investments, Intellia Therapeutics, Adicet Bio, Biotechnology, Investment Management